Bowel smooth muscle motility

Bowel smooth muscle motility is a physiological process characterized by the coordinated contraction and relaxation of the gastrointestinal (GI) tract's smooth muscle layers, which facilitates the propulsion and mixing of luminal contents [1]. This process is governed by a complex interplay between the enteric nervous system (ENS), the autonomic nervous system, and various neurohumoral factors such as serotonin, acetylcholine, and motilin [1, 2]. It is not a single molecular target but a physiological phenotype; however, it is frequently the primary endpoint for drugs targeting specific receptors like the 5-HT4 receptor (e.g., prucalopride) or the mu-opioid receptor (e.g., loperamide) [3, 5]. Dysregulation of this motility leads to clinical conditions such as irritable bowel syndrome (IBS), chronic idiopathic constipation, and gastroparesis [2, 4]. Therapeutic strategies aim to either stimulate motility (prokinetics) or inhibit it (antispasmodics or antidiarrheals) depending on the underlying pathology [3]. Because it represents a systemic physiological function rather than a specific protein or gene product, it is classified as a clinical or physiological phenotype in drug development contexts [1, 4].

Other names

Gastrointestinal motilityGI motilityIntestinal motilityIntestinal peristalsisGut motility

Pharmacological agents modulate bowel motility by acting as agonists or antagonists on specific molecular targets within the enteric nervous system or on the smooth muscle cells directly, such as 5-HT4 receptors, mu-opioid receptors, muscarinic M3 receptors, and guanylate cyclase-C [1, 3, 5].